Metabolomic evidence for the therapeutic effect of gentiopicroside in a corticosterone-induced model of depression.
Metabolomic evidence for the therapeutic effect of gentiopicroside in a corticosterone-induced model of depression.
复制标题
DOI:
10.1016/j.biopha.2019.109549
复制
发表时间:
2019-12
期刊:
影响因子:
--
通讯作者:
Tao Yao;Qin Cui;Zhichao Liu;C. Wang;Qi Zhang;Gaohua Wang
中科院分区:
文献类型:
--
作者:
Tao Yao;Qin Cui;Zhichao Liu;C. Wang;Qi Zhang;Gaohua Wang
BackgroundDepression is a disease that seriously threatens the quality of human life. To explore the effect of gentiopicroside on depression, this study investigated the therapeutic effect of gentiopicroside on corticosterone-induced depressionin vivoandin vitroby using metabolomic methods.MethodsA total of 36 rats were randomly assigned to three groups: a normal group, model group (depression), and treatment group (depression + gentiopicroside). Corticosterone was administrated to induce depression-like model rats. Morris water maze test was used to validated the behavior performance. The hippocampus of rats was obtained for metabolomic detection. Metabolites that were differentially expressed between the groups were extracted for Heatmap, Go, and pathway enrichment analyses. Finally, neuronal cells were cultured and examined to validated the effect of gentiopicroside.ResultsCorticosterone injured rats learning capacity, and decreased the levels of 5-HT, and reversed by gentiopicroside delivery. Metabolites obtained from the hippocampus of rats in the three groups were subjected to a principal component analysis (PCA). Go and pathway enrichment analyses revealed the involvement of sphingolipid metabolism et al. Gentiopicroside could inhibit apoptosis caused by corticosterone, and also decrease neuronal cell proliferation and BDNF levelsin vitro. Arachidonic acid (ARA) reversed the protective effect of gentiopicroside on neuronal cells.ConclusionThese findings suggest that gentiopicroside reduces apoptosis and increases the proliferation of hippocampus cells in depressed animals by regulating metabolites. Moreover, our study provides a new basis for the clinical treatment of depression and demonstrates the potential efficacy of gentiopicroside in this area of pathology.